Reduced Cancer Drug Reimbursements Don’t Impede Access – JAMA Study
This article was originally published in The Pink Sheet Daily
Executive Summary
2003-2006 Medicare claim review finds no evidence that lowering physician payments adversely affected access to care.
You may also be interested in...
Medicare Cancer Demo May Encourage Use Of EPO, Anti-Emetics
The Medicare program is earmarking $300 mil. for a "quality of care" demonstration project that should help smooth the transition to ASP-based reimbursement in 2005
Gilead Assistance Programs For HIV, Hep B Drugs Will Dial Back Reimbursement To 340B Providers
HIV community is pushing back against the change, arguing that revenue lost from reduced reimbursement will cripple providers, which use the extra funds for wrap-around patient support and services.
Higher Medicaid Rebates For Expedited Approvals Offer Modest Savings But Target Growing Concern
As MACPAC moves toward formal recommendations, a CBO analysis finds that differential Medicaid rebates for drugs approved through the accelerated pathway could save the federal government up to $1bn over five years.